Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist.

Abstract

In a double-blind study ten asthmatic patients with impaired lung function received the cysteinyl-leukotriene receptor antagonist ICI 204,219 (40 mg by mouth) and placebo in random order on 2 days at least 1 week apart. The increase in forced expiratory volume in 1 s (FEV1) above baseline was significantly greater after ICI 204,219 than after placebo. This effect persisted after nebulised salbutamol. These findings suggest that cysteinyl-leukotrienes are one of the causes of persistent bronchoconstriction in chronic asthma.

• Authors: K P Hui, N C Barnes
• Journal: Lancet (London, England) (Lancet) Vol. 337 Issue 8749 Pg. 1062-3 (May 04 1991) ISSN: 0140-6736 [Print] England
• PMID: 1673495 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Indoles
• Leukotriene Antagonists
• Phenylcarbamates
• Sulfonamides
• Tosyl Compounds
• Albuterol
• zafirlukast

Topics

• Administration, Inhalation
• Adult
• Airway Resistance (drug effects)
• Albuterol (administration & dosage, therapeutic use)
• Asthma (drug therapy, physiopathology)
• Bronchoconstriction (drug effects)
• Double-Blind Method
• Drug Evaluation
• Female
• Forced Expiratory Volume (drug effects)
• Humans
• Indoles
• Leukotriene Antagonists
• Male
• Middle Aged
• Phenylcarbamates
• Sulfonamides
• Tosyl Compounds (therapeutic use)